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Aim: Patient chart data from the USA during the period of January 2011 through October 2018 were
used to assess risk factors for progression in advanced ovarian cancer after response to first-line platinumbased chemotherapy. Patients & methods: Patients with stage III/IV ovarian cancer who completed firstline platinum-based chemotherapy after primary or interval debulking surgery were identified from the
Flatiron Health database. Cox proportional hazards modeling was used to assess associations between
baseline factors and time to next treatment (TTNT) or overall survival (OS). Results: Patients at stage IV or
who received interval debulking surgery had shorter TTNT and OS than patients at stage III or who received
primary debulking surgery, respectively. OS was worse in patients with residual disease and in BRCA wildtype. Conclusion: Multiple factors were associated with shorter TTNT or OS in this retrospective real-world
analysis.
First draft submitted: 6 January 2021; Accepted for publication: 14 July 2021; Published online:
11 August 2021
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Ovarian cancer (OC) has the highest mortality of all gynecologic cancers in the USA, with an estimated 21,750 newly
diagnosed cases and 13,940 deaths in 2020 [1]. Current standard of care for first-line treatment of OC is primary
debulking surgery (PDS) followed by chemotherapy (platinum plus a taxane, with or without bevacizumab) or
neoadjuvant chemotherapy (platinum plus a taxane, with or without bevacizumab) followed by interval debulking
surgery (IDS) and further therapy. Poly(ADP-ribose) polymerase inhibitors (PARPi) have been approved for
maintenance therapy in OC: niraparib is currently approved for all patients, olaparib is approved in patients with
deleterious BRCA mutations, while combination therapy with bevacizumab and olaparib is approved in patients
with homologous recombination deficient tumors.
Most patients respond to first-line treatment, but approximately 70% experience disease progression within
3 years [2]. Identifying prognostic factors that affect OC disease progression and survival is crucial to characterize
OC populations at higher risk who may benefit from new treatment regimens. The American Joint Committee on
Cancer (AJCC) recognizes International Federation of Gynecology and Obstetrics (FIGO) staging, histology and
grade as prognostic factors for survival in patients with OC [3]. For patients with advanced disease, residual disease
after primary cytoreduction is the most important prognostic factor for survival, with residual tumor size, number
of residual sites and residual disease locations also recognized as prognostic factors [3,4]. Despite guidance regarding
prognostic factors for survival, the AJCC does not assess prognostic factors for progression.
Data from electronic health records (EHR) are increasingly being used to augment results from clinical trials
by providing valuable real-world information [5]. Clinical trials are often conducted with highly selected patient
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populations with similar medical histories and are, therefore, limited in their generalizability to broader patient
populations [6]. Real-world databases aggregate medical information at the point of care, allowing for data capture
from a much larger, more diverse patient population. This is the first published study where we used the Flatiron
Health database to identify prognostic factors associated with risk of disease progression or death in patients with
advanced OC following response to first-line treatment.
Role of the funding source
The funder, GlaxoSmithKline, provided the data licensing and was involved in the study design, analysis, statistical
support and funding for medical writing support. GlaxoSmithKline is the manufacturer of the PARPi niraparib.
The authors had access to relevant aggregated study data and other information required to understand and
report research findings, such as study design, analytic plan and report, validated data tables and clinical study
report. The authors take responsibility for the presentation and publication of the research findings, have been
fully involved at all stages of publication and presentation development and are willing to take public responsibility
for all aspects of the work. All individuals included as authors and contributors who made substantial intellectual
contributions to the research, data analysis and publication or presentation development are listed appropriately.
The role of the sponsor in the design, execution, analysis, reporting and funding is fully disclosed. The authors’
personal interests, financial or nonfinancial, relating to this research and its publication have been disclosed.
Patients & methods
Data source

The Flatiron Health database is a longitudinal, demographically and geographically diverse database derived from
EHR data in the USA [7]. It contains health information from more than 265 cancer clinics across approximately 800
sites of care, representing more than 2 million active US patients with cancer. The deidentified patient-level EHR
data include structured data (e.g., laboratory values and prescribed drugs) in addition to unstructured data collected
via technology-enabled chart abstraction from physician notes and other unstructured documents (e.g., biomarker
reports). Rigorous quality control of structured and unstructured data is conducted to ensure that the data and
information are a reliable and reasonable approximation of the truth (inclusive of the heterogeneous story of the
real world). A real-time data mapping process is used to normalize structured data. For unstructured data, Flatiron
developed a methodology of technology-enabled chart abstraction. The process enables efficient processing of large
volumes of data, as well as centralized data quality and review, rapid reabstraction and incremental quality updates.
Although this study utilizes the Flatiron Health database, Flatiron Health was not involved in the study, its design,
analysis and interpretation or in the draft of this manuscript.
Study design & cohort definition

A retrospective observational study was designed to use real-world data to assess potential prognostic risk factors
affecting outcomes in patients with OC who completed first-line platinum-based chemotherapy. The outcomes
of interest were time to next treatment (TTNT), used as a surrogate for progression-free survival (PFS), and
overall survival (OS). We identified all women in the Flatiron Health database who had a diagnosis of OC as
defined by International Classification of Diseases (ICD) codes 183x, 158x (ICD-9) and C56x, C57.0x, C48x
(ICD-10) and at least two documented clinical visits for ovarian, fallopian tube or peritoneal cancer between 1
January 2011 and 31 October 2018, a period which corresponded to contemporary data when the project began.
Patients with stage III/IV OC who completed first-line platinum-based chemotherapy for five to ten cycles after
PDS, two to ten cycles after IDS or four to ten cycles without surgery were included. In order to capture the
natural history of OC progression on standard therapies prior to the introduction of PARPi to the market, patients
who received any PARPi as first-line treatment or as maintenance therapy after first-line treatment were excluded.
Only patients who started second-line treatment at least 2 months after completion of first-line treatment were
selected and were considered to be in complete response or partial response to front-line platinum therapy. These
criteria were designed to select patients who responded to first-line platinum therapy, regardless of whether the
patient would ultimately be considered platinum sensitive or platinum resistant at the time of progression, and
to exclude patients who were refractory to first-line platinum because patients with primary platinum-refractory
disease are not reflective of the typical disease course for OC. Inclusion criteria for the Flatiron Health database
OC cohort includes histology of one of the following: serous, mucinous, clear cell, transitional cell, endometrioid,
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Table 1. Study attrition.
Attrition

Patients, n (%)

Ovarian cancer cohort (1 January 2011 to 31 October 2018)

5535 (100)

Patients had first-line treatment

4081 (74)

Patients had first-line platinum-based chemotherapy treatment

3499 (63)

Patients had stage III or IV disease

2314 (42)

Excluded patients with an unknown surgery date

2312 (42)

Platinum-based chemotherapy treatment criteria:
a. Patients without surgery in the first line must have had ≥4 and ≤10 cycles of platinum-based therapy
b. Patients treated with primary debulking surgery must have had ≥5 and ≤10 cycles of platinum-based therapy
c. Patients must have had ≥2 and ≤10 postoperative cycles of platinum-based therapy after interval debulking surgery
Patients naive to first-line PARP inhibitor treatment and PARP maintenance therapy after first-line treatment
Patients who had active surveillance after first-line treatment
Excluded patients who started second-line treatment within 2 months

1346 (24)

1345 (24)
1217 (22)
1064 (19)

Sensitivity analysis
Excluded patients who started second-line treatment within 3 months

1018 (18)

PARP: Poly(ADP-ribose) polymerase.

epithelial NOS, borderline or unknown/undocumented. The index date was defined as the last date of the first-line
platinum-based chemotherapy treatment.
Analysis

The primary outcomes of interest were TTNT and OS. TTNT was used as a surrogate end point for PFS, which
was defined as the time from the index date to the start date of second-line treatment or death or the date of
a patient’s last confirmed activity (last structured visit, laboratory test or medication administration), whichever
occurred first. OS was defined as the time from the index date to death or the date of the patient’s last confirmed
activity (last structured visit, laboratory test, medication administration or abstracted end date for an oral span),
whichever occurred first [8,9]. The following potential risk factors were included in the analysis to evaluate impact on
patient prognosis: BRCA mutation status (identified as either somatic or germline mutation), history of neoadjuvant
chemotherapy, stage of OC at initial diagnosis, presence of residual disease after PDS or IDS (if debulking surgery
was described in the patient record as suboptimal or was unknown, patients were considered as having residual
disease; if surgeries were described as optimal, patients were considered as having no residual disease), Eastern
Cooperative Oncology Group (ECOG) performance status (using the most recent evaluation within the last
180 days), age (at index date), platelet count, hemoglobin and neutrophil count (using most recent values [within
28 days prior to index]). Potential risk factors were based on enrollment criteria for enrolling and ongoing trials in
first-line OC when the analysis was designed.
First, we compared patient demographics and baseline characteristics by TTNT and OS status using descriptive
statistics. Subsequently, the association between prognostic risk factors and disease progression in the real world
was assessed using a multivariable model for all selected variables. A hazard ratio (HR) for each potential risk
factor was calculated to assess its association with disease progression. Potential risk factors were selected based
on literature, clinical experience and ongoing trials. In cases where the 90% CI excluded 1.0, risk factors were
reported as significant. Finally, a stratified Kaplan–Meier analysis was performed to compare patient prognosis of
some key risk factors (BRCA mutation status, history of neoadjuvant chemotherapy and disease stage at diagnosis).
A sensitivity analysis was conducted that included patients who started second-line treatment at least 3 months
after first-line treatment.
Results
We retrospectively identified 5535 patients diagnosed with OC between January 2011 and November 2018
(Table 1). Of these, 1064 patients met the inclusion criteria for the study. For OC, 87% of patients in the database
were from community practices and 13% of patients were from academic centers. Demographics and baseline
characteristics of patients included in the TTNT and OS analyses are shown in Tables 2 & 3. In the Flatiron Health
database OC cohort, 76% of the patients had serous histology, as shown in Tables 2 & 3.
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Table 2. Patient demographics and baseline characteristics for time to next treatment.
Characteristic

Time to next treatment
Event (n = 645), n (%)

No event (n = 419), n (%)

18–65

297 (46)

192 (46)

≥66

348 (54)

227 (54)

489 (76)

320 (76)

Age (years)

p-value

0.94

Race

0.20

White
Black

33 (5)

18 (4)

Asian

22 (3)

10 (2)

Hispanic/Latino

1 (⬍1)

0 (0)

Other

65 (10)

34 (8)

Unknown

35 (5)

37 (9)

Tumor BRCA status

0.42

BRCAmut†

90 (14)

BRCAwt

292 (45)

177 (42)

BRCA unknown

263 (41)

188 (45)

393 (61)

274 (65)

Neoadjuvant

165 (26)

96 (23)

No surgery

87 (13)

49 (12)

54 (13)

Therapy type

0.34

Adjuvant

Stage of disease at initial diagnosis

0.003

III

449 (70)

326 (78)

IV

196 (30)

93 (22)

No visible gross

292 (45)

191 (46)

Visible gross

353 (55)

228 (54)

0–1

323 (50)

239 (57)

2–4

50 (8)

30 (7)

Missing

272 (42)

150 (36)

150 (23)

90 (21)

≥150

326 (51)

179 (43)

Missing

169 (26)

150 (36)

⬍10

78 (12)

41 (10)

≥10

536 (83)

359 (86)

Missing

31 (5)

19 (5)

57 (9)

38 (9)

Residual disease after PDS/IDS

0.92

ECOG performance status

0.08

Platelet count (×109 /l)
⬍150

0.003

Hemoglobin (g/dl)

0.48

Neutrophil count (×109 /l)
⬍1.5

0.01

≥1.5

223 (35)

183 (44)

Missing

365 (57)

198 (47)

Ovarian

560 (87)

366 (87)

Fallopian tube

43 (7)

37 (9)

0.19

Primary peritoneal

64 (10)

46 (11)

0.58

Serous

488 (76)

316 (75)

Borderline, mucinous or transitional cell

15 (2)

9 (2)

Clear cell

12 (2)

9 (2)

Tumor site

Histology

0.80

0.93

† Approximately

3% of BRCA results were genetic variants of unknown significance or favored polymorphism grouped as BRCAmut.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; ECOG: Eastern Cooperative Oncology Group; IDS: Interval debulking surgery; PDS: Primary debulking surgery.
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Table 2. Patient demographics and baseline characteristics for time to next treatment (cont.).
Characteristic

Time to next treatment

p-value

Event (n = 645), n (%)

No event (n = 419), n (%)

Endometrioid

16 (2)

15 (4)

Epithelial NOS

100 (16)

62 (15)

Unknown/not documented

14 (2)

8 (2)

† Approximately

3% of BRCA results were genetic variants of unknown significance or favored polymorphism grouped as BRCAmut.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; ECOG: Eastern Cooperative Oncology Group; IDS: Interval debulking surgery; PDS: Primary debulking surgery.

Variable
BRCA mutation status
BRCAwt (vs BRCAmut)
BRCAunk (vs BRCAmut)
Treatment modality
IDS (vs PDS)
No surgery (vs PDS)
Disease stage
IV (vs lll)
Residual disease
Visible gross (vs no visible gross)
ECOG performance status
0–1 (vs 2–4)
Missing (vs 2–4)
Age
18–65 years (vs ≥66 years)
Platelet count
≥150,000/μl (vs <150,000/μl)
Missing (vs <150,000/μl)
Hemoglobin
≥10 g/dl (vs <10 g/dl)
Missing (vs <10 g/dl)
Neutrophil count
≥1500/μl (vs <1500/μl)
Missing (vs <1500/μl)

HR (90% Cl)

p-value

1.16 (0.95–1.42)
1.20 (0.97–1.47)

0.23
0.15

1.37 (1.17–1.62)
2.40 (1.92–3.00)

0.001
<0.0001

1.26 (1.03–1.47)

0.01

0.99 (0.86–1.14)

0.89

0.88 (0.68–1.13)
0.90 (0.69–1.17)

0.40
0.50

1.08 (0.94–1.23)

0.36

1.11 (0.94–1.31)
1.02 (0.84–1.25)

0.32
0.85

0.74 (0.60–0.90)
0.86 (0.59–1.25)

0.01
0.50

0.93 (0.73–1.20)
0.92 (0.72–1.18)

0.65
0.59

0.5

1.0

1.5

2.0

2.5

3.0

HR

Figure 1. Cox proportional hazards model analysis of time to next treatment. The multivariable model adjusted for
all variables shown in the forest plot. An HR greater than 1.0 indicates a shorter time to next treatment.
BRCAmut: BRCA mutated; BRCAunk: BRCA unknown; BRCAwt: BRCA wild-type; ECOG: Eastern Cooperative Oncology
Group; HR: Hazard ratio; IDS: Interval debulking surgery; PDS: Primary debulking surgery.

Time to next treatment

Patients who received neoadjuvant chemotherapy (as defined by receiving IDS) had a shorter TTNT than those
who received PDS, after adjusting for other covariates (IDS vs PDS: HR: 1.37, 90% CI: 1.17–1.62) (Figure 1).
Patients who received no surgery also had a shorter TTNT (no surgery vs PDS: HR: 2.40, 90% CI: 1.92–3.00).
Patients with stage IV disease had a shorter TTNT than patients with stage III disease, after adjusting for other
covariates (stage IV vs stage III: HR: 1.26, 90% CI: 1.08–1.47) (Figure 1).
The median TTNT was 13.8 months for patients who received PDS and 10.2 months for patients who received
IDS (Figure 2C). The median TTNT was 12.9 months for patients with stage III disease and 8.9 months for
patients with stage IV disease (Figure 2B).
Overall survival

Consistent with TTNT results, patients who received IDS had a shorter OS than those who received PDS (IDS
vs PDS: HR: 1.64, 90% CI: 1.31–2.04), after adjusting for other covariates (Figure 3). Patients who received no
surgery had a shorter OS than those who received PDS (no surgery vs PDS: HR: 2.88, 90% CI: 2.19–3.80).
Patients with stage IV disease had a shorter OS than patients with stage III disease (stage IV vs stage III: HR: 1.24,
90% CI: 1.01–1.51).
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Table 3. Patient demographics and baseline characteristics for overall survival.
Characteristic

Overall survival
Event (n = 372), n (%)

No event (n = 692), n (%)

18–65

155 (42)

334 (48)

≥66

217 (58)

358 (52)

289 (78)

520 (75)

Age (years)

p-value

0.04

Race

0.36

White
Black

20 (5)

31 (4)

Asian

10 (3)

22 (3)

Hispanic/Latino

0 (0)

1 (⬍1)

Other

36 (10)

63 (9)

Unknown

17 (5)

55 (8)
⬍0.0001

Tumor BRCA status
BRCAmut†

35 (9)

BRCAwt

148 (40)

321 (46)

BRCA unknown

189 (51)

262 (38)

206 (55)

461 (67)

Neoadjuvant

94 (25)

167 (24)

No surgery

72 (19)

64 (9)

109 (16)

⬍0.0001

Therapy type
Adjuvant

⬍0.0001

Stage of disease at initial diagnosis
III

242 (65)

533 (77)

IV

130 (35)

159 (23)

No visible gross

144 (39)

339 (49)

Visible gross

228 (61)

353 (51)

0–1

171 (46)

391 (57)

2–4

34 (9)

46 (7)

Missing

167 (45)

255 (37)

87 (23)

153 (22)

≥150

198 (53)

307 (44)

Missing

87 (23)

232 (34)

⬍10

43 (12)

76 (11)

≥10

306 (82)

589 (85)

Missing

23 (6)

27 (4)

25 (7)

70 (10)

Residual disease after PDS/IDS

0.001

ECOG performance status

0.004

Platelet count (×109 /l)
⬍150

0.002

Hemoglobin (g/dl)

0.22

Neutrophil count (×109 /l)
⬍1.5

0.01

≥1.5

129 (35)

277 (40)

Missing

218 (59)

345 (50)

Ovarian

326 (88)

600 (87)

Fallopian tube

23 (6)

57 (8)

0.23

Primary peritoneal

37 (10)

73 (11)

0.76

Serous

269 (72)

535 (77)

Borderline, mucinous or transitional cell

11 (3)

13 (2)

Tumor site

Histology

0.67

0.0069

† Approximately

3% of BRCA results were genetic variants of unknown significance or favored polymorphism grouped as BRCAmut.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; ECOG: Eastern Cooperative Oncology Group; IDS: Interval debulking surgery; PDS: Primary debulking surgery.
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Table 3. Patient demographics and baseline characteristics for overall survival (cont.).
Characteristic

Overall survival
Event (n = 372), n (%)

p-value

No event (n = 692), n (%)

Clear cell

8 (2)

13 (2)

Endometrioid

4 (1)

27 (4)

Epithelial NOS

68 (18)

94 (14)

Unknown/not documented

12 (3)

10 (1)

† Approximately

Probability of time to
next treatment

1.0
0.9

BRCAmut: median 14.2 months (95% CI: 13–18)
BRCAwt: median 11.6 months (95% CI: 10–12)

0.8

HR (BRCAwt vs BRCAmut) = 1.2 (95% CI: 1.0–1.5)

0.7

p < 0.10

0.6
0.5
0.4
0.3
0.2

1.0
0.9

Stage III: median 12.9 months (95% CI: 12–15)
Stage IV: median 8.9 months (95% CI: 8–10)

0.8

HR (stage IV vs III) = 1.5 (95% CI: 1.3–1.8)
p < 0.0001

0.7
0.6
0.5
0.4
0.3
0.2
0.1

0.1

0.0

0.0
0

6

12

18

24

30

36

Months
No. at risk:
BRCAmut 144 115 72 41 28 23 15
BRCAwt
469 301 161 106 78 61 46

42
11
34

48
9
25

54
5
16

60
1
13

18

24

36

42

48

54

60

Months
No. at risk:
Stage III
775 516 301 192 139 114 81
Stage IV
289 154 74 52 34 26 20

65
14

47
10

35
6

22
3

0

6

12

30

PDS: median 13.8 months (95% CI: 12–16)

1.0
0.9
Probability of time to
next treatment

Probability of time to
next treatment

3% of BRCA results were genetic variants of unknown significance or favored polymorphism grouped as BRCAmut.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; ECOG: Eastern Cooperative Oncology Group; IDS: Interval debulking surgery; PDS: Primary debulking surgery.

IDS: median 10.2 months (95% CI: 9–12)
No surgery: median 6.1 months (95% CI: 4–8)

0.8

HR (IDS vs PDS) = 1.5 (95% CI: 1.2–1.8)

0.7

HR (no surgery vs PDS) = 2.7 (95% CI: 2.2–3.5)

0.6

p < 0.0001

0.5
0.4
0.3
0.2
0.1
0.0
0

6

12

No. at risk:

18

24

30

36

42

48

54

60

68
8
3

51
5
1

37
4
0

24
1

Months

PDS
667 473 283 187 141 117 85
IDS
261 151 77 48 26 17 12
No surgery 136 46 15
9
6
6
4

Figure 2. Kaplan–Meier analysis of time to next treatment. (A) By BRCA mutation status. (B) By disease stage. (C) By
treatment modality.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; HR: Hazard ratio; IDS: Interval debulking surgery; PDS: Primary
debulking surgery; TTNT: Time to next treatment.

Median OS was 49 months in patients who received PDS and 32 months in patients who received IDS
(Figure 4C). Median OS was 43 and 29 months in patients with stage III and stage IV disease, respectively
(Figure 4B).
In addition to risk factors for progression, we identified prognostic factors that affected OS. Patients with residual
disease after debulking surgery had a shorter OS than those without residual disease (visible gross residual disease
vs no visible gross residual disease: HR: 1.27, 90% CI: 1.05–1.55) (Figure 3). Patients with BRCA wild-type
(BRCAwt) disease had a worse OS than patients with BRCA mutated (BRCAmut) disease (BRCAwt vs BRCAmut:
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Variable
BRCA mutation status
BRCAwt (vs BRCAmut)
BRCAunk (vs BRCAmut)
Treatment modality
IDS (vs PDS)
No surgery (vs PDS)
Disease stage
IV (vs III)
Residual disease
Visible gross (vs no visible gross)
ECOG performance status
0–1 (vs 2–4)
Missing (vs 2–4)
Age
18–65 years (vs ≥66 years)
Platelet count
≥150,000/μl (vs <150,000/μl)
Missing (vs <150,000/μl)
Hemoglobin
≥10 g/dl (vs <10 g/dl)
Missing (vs <10 g/dl)
Neutrophil count
≥1500/μl (vs <1500/μl)
Missing (vs <1500/μl)

HR (90% CI)

p-value

1.37 (1.00–1.87)
2.28 (1.67–3.10)

0.10
<0.0001

1.64 (1.31–2.04)
2.88 (2.19–3.80)

0.0002
<0.0001

1.24 (1.01–1.51)

0.09

1.27 (1.05–1.55)

0.04

0.75 (0.54–1.03)
0.84 (0.61–1.15)

0.13
0.36

1.16 (0.97–1.39)

0.18

1.12 (0.90–1.39)
0.97 (0.74–1.27)

0.40
0.84

0.71 (0.54–0.93)
0.95 (0.59–1.51)

0.04
0.85

1.28 (0.89–1.84)
1.20 (0.84–1.71)

0.26
0.40

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

HR

Figure 3. Cox proportional hazards model analysis of overall survival. The multivariable model adjusted for all
variables shown in the forest plot. An HR greater than 1.0 indicates a shorter OS.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; BRCAunk: BRCA unknown; ECOG: Eastern Cooperative Oncology
Group; HR: Hazard ratio; IDS: Interval debulking surgery; OS: Overall survival; PDS: Primary debulking surgery.

HR: 1.37, 90% CI: 1.00–1.87) (Figure 3). Median OS was not reached in patients with a BRCAmut and was
43 months in patients with BRCAwt tumors (Figure 4A).
A sensitivity analysis of TTNT and OS excluded 46 patients from the main analysis who received second-line
treatment within 3 months of finishing first-line treatment (data not shown). The results of the sensitivity analysis
were similar to the results of the main analysis for the 1018 patients who met the inclusion criteria after this
exclusion.
Discussion
In this retrospective analysis of a real-world dataset, prognostic factors for disease progression and overall survival
in patients with advanced ovarian cancer were evaluated. By excluding patients who received a PARPi as first-line
treatment or maintenance therapy after first-line treatment, we were able to view the association between BRCAmut
and BRCAwt status and TTNT, which is a surrogate for PFS and OS. BRCAwt status was associated with a decrease
in OS. Receipt of neoadjuvant chemotherapy, higher FIGO disease stage at diagnosis and presence of residual
disease after surgery were also associated with a shorter TTNT or OS. These real-world data confirm prognostic
factors for survival that have been previously identified in meta-analyses of clinical trials [10,11], as well as those
recognized by the AJCC [3].
By including TTNT as a surrogate for PFS, data from the present analysis expand on previous findings in
identifying prognostic factors for disease recurrence – an important factor in OC given that approximately 70%
of patients in this analysis experienced disease recurrence at 3 years (median time to recurrence: 14.2 months
in BRCAmut; 11.6 months in BRCAwt) and that OC is considered incurable after recurrence [2]. Patients with
BRCAmut tend to have a longer window of platinum sensitivity than patients with BRCAwt, which is believed to
drive the longer OS seen in the BRCAmut population. The present analysis demonstrates a 3-month difference in
median TTNT between BRCAmut and BRCAwt, which is small but reflects that a greater percentage of BRCAmut
patients will be classified as platinum sensitive to their last platinum regimen.
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Figure 4. Kaplan–Meier analysis of overall survival. (A) By BRCA mutation status. (B) By disease stage. (C) By
treatment modality.
BRCAmut: BRCA mutated; BRCAwt: BRCA wild-type; HR: Hazard ratio; IDS: Interval debulking surgery; NE: Not
evaluable; PDS: Primary debulking surgery.

This study also provides novel insights into the OC population in real-world clinical practice settings rather than
as a more selected clinical trial population. Clinical trial and real-world data cannot be directly compared. However,
the present analysis indicates concordance between prognostic factors identified in analyses of clinical trials and
real-world practice. As such, this analysis provides useful insight into how clinical trial data are representative of
patients in a real-world setting.
Real-world databases have limitations related to the type of data collected and the quality control of data within
the network. Here, it was necessary to use TTNT as a proxy for PFS because of inherent limitations in data
capture within the Flatiron Health database. TTNT has been used previously as a proxy for PFS in real-world
analyses of patients with multiple myeloma [12,13]. In addition, patients in the database might seek care outside the
Flatiron Health network, making complete patient histories difficult to capture. During the period of this analysis,
many large Phase III clinical trials were enrolling patients, particularly trials with PARPi. Bias in the population of
patients receiving treatment in Flatiron-participating centers versus those being recruited to clinical trials may exist,
since patients in this analysis were less likely to meet the inclusion criteria for highly selected clinical trial patient
populations. This study is also limited in that the Flatiron Health database is representative of US patients only;
therefore, these results may not apply to global populations where patient demographics or first-line treatments may
differ considerably. One further limitation is the percentage of patients included in the study who had unknown
tumor BRCA status (42% of all patients) and/or missing ECOG status (40% of all patients). Although unavoidable
due to the study design, this limitation may impact the association of those risk factors with TTNT or OS.
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Despite the limitations, real-world data from EHR provide a useful supplement to clinical trial data by allowing
for large retrospective analyses that are not possible within a clinical trial setting. Based on the selection criteria
used, patients from this real-world dataset should be similar to those in the placebo arm of the SOLO1 and PRIMA
trials of maintenance treatment after response to first-line platinum-based chemotherapy in patients with OC [14].
In the PRIMA trial, median PFS for the placebo arm was 8.2 months, whereas in the SOLO1 trial, median PFS
for the placebo arm was 13.8 months [14,15]. However, the populations of the two trials had distinct differences.
All patients enrolled in the SOLO1 trial had deleterious germline or somatic BRCA1/2 mutation. In addition,
those patients with stage IV disease had undergone either biopsy or up-front or interval cytoreductive surgery [14].
The PRIMA trial, in contrast, did not require BRCA1/2 mutation for enrollment and furthermore, was open to
patients with any stage IV disease, which led to the PRIMA trial enrolling patients at high risk for progression [15].
Because of the differences in these trial populations, not only is it impossible to directly compare SOLO1 with
PRIMA, it is also impossible to directly compare these two trials to the real-world data presented in this analysis. As
PARPi usage and approvals in the first-line therapy setting increase, we hope to assess the utility of these additional
prognostic factors derived from real-world data.
Conclusion
In this real-world analysis from the Flatiron Healthcare database of patients identified with stage III/IV OC who
completed first-line platinum-based chemotherapy after surgery, IDS, disease stage at diagnosis, residual disease
after PDS or IDS and BRCAwt were associated with a shorter TTNT or OS.
Summary points
• Most patients with ovarian cancer (OC) respond to first-line treatment, but approximately 70% experience
disease progression within 3 years.
• Although there is guidance regarding prognostic factors for survival in patients with OC, there is no guidance
regarding prognostic factors for progression, which is crucial to identify patients who are at higher risk of
progression and may benefit from new treatment regimens.
• Real-world databases allow for data capture from a much larger and more diverse patient population than
clinical studies.
• In a real-world dataset, patients with OC receiving interval debulking surgery had a shorter time to next
treatment (TTNT) or overall survival than patients with OC who received primary debulking surgery.
• Patients with stage IV OC had a shorter TTNT and OS than patients with stage III OC in the real-world dataset.
• In this dataset, BRCAwt status was associated with a decrease in OS in ovarian cancer.
• Higher FIGO (International Federation of Gynecology and Obstetrics) stage, neoadjuvant chemotherapy, and
residual disease after surgery were associated with shorter TTNT/OS in OC in the dataset.
• Real-world data confirmed prognostic factors for survival in OC that had been previously identified in clinical
trials.

Author contributions
SN Westin, M Louie-Gao, D Gupta and PH Thaker designed the study. M Louie-Gao compiled the data and did statistical analysis.
SN Westin, M Louie-Gao, D Gupta and PH Thaker prepared the manuscript.
Financial & competing interests disclosure
This study was supported by GlaxoSmithKline. SN Westin funding: NIH SPORE for Ovarian Cancer (P50 CA083639), Andrew
Sabin Family Fellowship (no grant number), GOG Foundation Scholar Investigator Award (no grant number), NCI (CA217685 and
CA16672). SN Westin reports personal fees from Agenus, GlaxoSmithKline, AstraZeneca, Circulogene, Roche/Genentech, Medscape, Clovis Oncology, Watermark Research Partners, Gerson Lehrman Group, Vaniam Group, Merck, Pfizer, BioAscend, Novartis,
Takeda, Zentalis, Eisai; research support outside the submitted work from ArQule, AstraZeneca, Novartis, Bayer, GlaxoSmithKline,
Cotinga Pharmaceuticals, Clovis Oncology, Roche/Genentech. PH Thaker reports personal fees and other from Stryker; personal
fees from Celsion, GlaxoSmithKline, Clovis, AstraZeneca, AbbVie, Iovance Biotherapeutics, Genentech, Immunogen, Merck; research support from Merck and GlaxoSmithKline outside the submitted work. M Louie-Gao and D Gupta are current or former
employees of GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from
those disclosed.

4272

Future Oncol. (2021) 17(32)

future science group

Risk factors after first-line platinum-based chemotherapy in patients in the USA with ovarian cancer

Short Communication

Medical writing and editorial assistance, funded by GlaxoSmithKline (MA, USA) and coordinated by H Ostendorff-Bach of
GlaxoSmithKline, were provided by N Renner and M Kacillas of Ashfield Healthcare Communications (CT, USA) and AM Schreiber
of GlaxoSmithKline.

Ethical conduct of research
This study used a deidentified dataset provided by Flatiron Health. The data remained deidentified throughout the analyses to
protect patient confidentiality. Provisions were in place to prevent re-identification of deidentified data to ensure patient confidentiality.

Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References
Papers of special note have been highlighted as: • of interest
1.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).

2.

Ledermann JA, Raja FA, Fotopoulou C et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi24–vi32 (2013).

3.

American Joint Committee on Cancer (AJCC). Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma. 8th Edition. AJCC, IL, USA
(2017).

4.

Polterauer S, Vergote I, Concin N et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages
IIA-IV: analysis of the OVCAD data. Int. J. Gynecol. Cancer. 22(3), 380–385 (2012).

•

Demonstrates that the size of residual disease after cytoreduction is a crucial prognostic indicator in ovarian cancer.

5.

Berger ML, Curtis MD, Smith G, Harnett J, Abernethy AP. Opportunities and challenges in leveraging electronic health record data in
oncology. Future Oncol. 12(10), 1261–1274 (2016).

•

Discusses the challenges of using electronic health record data to obtain information in clinical research in oncology.

6.

Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 151(3), 203–205
(2009).

7.

Flatiron. Flatiron Health EHR-derived database. https://flatiron.com/real-world-evidence/

8.

Curtis MD, Griffith SD, Tucker M et al. Development and validation of a high-quality composite real-world mortality endpoint. Health
Serv. Res. 53(6), 4460–4476 (2018).

•

Discusses how data quality and completeness in electronic health databases impact the ability of the data to yield reliable
real-world evidence.

9.

Zhang Q, Gossai A, Monroe S, Nussbaum NC, Parrinello CM. Validation analysis of a composite real-world mortality endpoint for US
cancer patients. Presented at: 111th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, USA (22 June–24
June 2020). Abstract nr 5772. https://www.abstractsonline.com/pp8/#!/9045/presentations/5772/1

•

Looked at the sensitivity, specificity and date accuracy of the composite mortality variable across cancer types in the Flatiron
Health database.

10. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a
meta-analysis. Gynecol. Oncol. 103(3), 1070–1076 (2006).
11. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of
neoadjuvant chemotherapy and interval cytoreduction. Gynecol. Oncol. 104(2), 480–490 (2007).
12. Chen CC, Parikh K, Abouzaid S et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or
refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J. Manag. Care Spec. Pharm. 23(2), 236–246 (2017).
13. Rifkin RM, Medhekar R, Amirian ES et al. A real-world comparative analysis of carfilzomib and other systemic multiple myeloma
chemotherapies in a US community oncology setting. Ther. Adv. Hematol. 10, (2019). https://doi.org/10.1177/2040620718816699
•

Demonstrates the feasibilty of estimating a time to next treatment through the use of electronic health records and comparing it
to the progression-free survival observed in a clinical trial. The study looks at patients receiving carfilzomib for multiple
myeloma and the Phase III ASPIRE trial.

14. Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J.
Med. 379(26), 2495–2505 (2018).
•

Demonstrates that the use of maintenance olaparib provided a benefit to progression-free survival in women with newly
diagnosed advanced ovarian cancer and a BRCA1/2 mutation.

future science group

www.futuremedicine.com

4273

Short Communication

Westin, Louie-Gao, Gupta & Thaker
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